Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlie Schmidt

Showing results (51-60 of 113) with videos related to

Pageof 12
Sort By:
Journal of the National Cancer Institute|July 28, 2018
M. D. Anderson Breaks With IBM Watson, Raising Questions About Artificial Intelligence in OncologyCharlie Schmidt
Journal of the National Cancer Institute|March 2, 2011
KILLIN gene discovery stirs up research on Cowden syndrome cancersCharlie Schmidt
Journal of the National Cancer Institute|January 19, 2011
Abiraterone and MVD3100 take androgen deprivation to a new levelCharlie Schmidt
Journal of the National Cancer Institute|December 9, 2010
How to handle positive sentinel nodes?Charlie Schmidt
Nature Biotechnology|August 10, 2007
Clinical setbacks for toll-like receptor 9 agonists in cancerCharlie Schmidt
Journal of the National Cancer Institute|December 17, 2011
Challenges ahead for companion diagnosticsCharlie Schmidt
Journal of the National Cancer Institute|August 20, 2011
Ovarian cancer treatments on the horizonCharlie Schmidt
Journal of the National Cancer Institute|August 20, 2011
CA-125: a biomarker put to the testCharlie Schmidt
Journal of the National Cancer Institute|February 16, 2006
Researchers exploring faster alternatives to 2-year test for carcinogenicityCharlie Schmidt
Journal of the National Cancer Institute|May 4, 2006
Immune system's Toll-like receptors have good opportunity for cancer treatmentCharlie Schmidt
Pageof 12

Showing results (51-60 of 113) with videos related to

Sort By:
Pageof 12
Journal of the National Cancer Institute|July 28, 2018
M. D. Anderson Breaks With IBM Watson, Raising Questions About Artificial Intelligence in OncologyCharlie Schmidt
Journal of the National Cancer Institute|March 2, 2011
KILLIN gene discovery stirs up research on Cowden syndrome cancersCharlie Schmidt
Journal of the National Cancer Institute|January 19, 2011
Abiraterone and MVD3100 take androgen deprivation to a new levelCharlie Schmidt
Journal of the National Cancer Institute|December 9, 2010
How to handle positive sentinel nodes?Charlie Schmidt
Nature Biotechnology|August 10, 2007
Clinical setbacks for toll-like receptor 9 agonists in cancerCharlie Schmidt
Journal of the National Cancer Institute|December 17, 2011
Challenges ahead for companion diagnosticsCharlie Schmidt
Journal of the National Cancer Institute|August 20, 2011
Ovarian cancer treatments on the horizonCharlie Schmidt
Journal of the National Cancer Institute|August 20, 2011
CA-125: a biomarker put to the testCharlie Schmidt
Journal of the National Cancer Institute|February 16, 2006
Researchers exploring faster alternatives to 2-year test for carcinogenicityCharlie Schmidt
Journal of the National Cancer Institute|May 4, 2006
Immune system's Toll-like receptors have good opportunity for cancer treatmentCharlie Schmidt
Pageof 12